Details

Autor(en) / Beteiligte

• Tallantyre, Emma C
• Dobson, Ruth
• Froud, Joseph L J
• St John, Frederika A
• Anderson, Valerie M
• Arun, Tarunya
• Buckley, Lauren
• Evangelou, Nikos
• Ford, Helen L
• Galea, Ian
• George, Sumi
• Gray, Orla M
• Hibbert, Aimee M
• Hu, Mo
• Hughes, Stella E
• Ingram, Gillian
• Kalra, Seema
• Lim, Chia-Hui E
• Mathews, Joela T M
• McDonnell, Gavin V
• Mescall, Naomi
• Norris, Sam
• Ramsay, Stephen J
• Rice, Claire M
• Russell, Melanie J
• Shawe-Taylor, Marianne J
• Williams, Thomas E
• Harding, Katharine E
• Robertson, Neil P

Titel

Real-world persistence of multiple sclerosis disease-modifying therapies

Ist Teil von

• European journal of neurology, 2024-04, p.e16289-e16289

Ort / Verlag

England

Erscheinungsjahr

2024

Link zum Volltext

Quelle

Wiley Online Library Journals Frontfile Complete

Beschreibungen/Notizen

• Treatment persistence is the continuation of therapy over time. It reflects a combination of treatment efficacy and tolerability. We aimed to describe real-world rates of persistence on disease-modifying therapies (DMTs) for people with multiple sclerosis (pwMS) and reasons for DMT discontinuation. Treatment data on 4366 consecutive people with relapse-onset multiple sclerosis (MS) were pooled from 13 UK specialist centres during 2021. Inclusion criteria were exposure to at least one MS DMT and a complete history of DMT prescribing. PwMS in blinded clinical trials were excluded. Data collected included sex, age at MS onset, age at DMT initiation, DMT treatment dates, and reasons for stopping or switching DMT. For pwMS who had received immune reconstituting therapies (cladribine/alemtuzumab), discontinuation date was defined as starting an alternative DMT. Kaplan-Meier survival analyses were used to express DMT persistence. In 6997 treatment events (1.6 per person with MS), median time spent on any single maintenance DMT was 4.3 years (95% confidence interval = 4.1-4.5 years). The commonest overall reasons for DMT discontinuation were adverse events (35.0%) and lack of efficacy (30.3%). After 10 years, 20% of people treated with alemtuzumab had received another subsequent DMT, compared to 82% of people treated with interferon or glatiramer acetate. Immune reconstituting DMTs may have the highest potential to offer a single treatment for relapsing MS. Comparative data on DMT persistence and reasons for discontinuation are valuable to inform treatment decisions and in personalizing treatment in MS.